Roche - Latest News [Page 2]

New data supports case for funding MabThera®(

Monday, 10 November 2008, 2:05 pm | Roche

New data presented at the American College of Rheumatology’s annual meeting in San Francisco is good news for New Zealanders suffering from moderate to severe Rheumatoid Arthritis (RA), who have failed to respond to the most commonly prescribed biologic ... More >>

Herceptin decision continues to disappoint

Thursday, 7 August 2008, 4:18 pm | Roche

Roche Products (NZ) Ltd is very disappointed that New Zealand women with early HER2 positive breast cancer will continue to miss out on the internationally accepted 52 weeks' treatment with Herceptin(r) (trastuzumab). More >>

Judge orders review of Herceptin decision

Thursday, 3 April 2008, 3:40 pm | Roche

Roche Products (New Zealand) Limited welcomes Justice Gendall’s directive to set aside PHARMAC’s decision not to fund 52 weeks of Herceptin® for the treatment of early HER2 positive breast cancer. Svend Petersen, managing director of Roche, ... More >>

Breast cancer - Know your type

Wednesday, 24 October 2007, 3:53 pm | Roche

A leading local breast surgeon says it is important that women know about their type of breast cancer, as well as relevant testing and treatment options if they want to give themselves the best chance of a full recovery. More >>

Influenza treatment now available from pharmacies

Monday, 14 May 2007, 2:58 pm | Roche

This winter, for the first time in New Zealand, Tamiflu® (oseltamivir), an influenza (flu) treatment, will be available directly from pharmacists during the influenza season. More >>

Herceptin decision is budget based

Tuesday, 20 March 2007, 2:51 pm | Roche

Roche Products (New Zealand) Limited believes PHARMAC's decision to fund Herceptin® (trastuzumab) for nine weeks as opposed to the internationally accepted 52 week treatment period is a compromise, made for reasons of budget control as opposed to clinical ... More >>

Roche Products on Nine Weeks funding for Herceptin

Friday, 16 February 2007, 11:57 am | Roche

PHARMAC is misleading the New Zealand public and parliament about the nine week trial data. Roche is seeking an urgent meeting with the Minister of Health to discuss the implications of PHARMAC’s announcement. This has the potential to be this Labour ... More >>

New website sheds light on breast cancer

Tuesday, 17 October 2006, 3:20 pm | Roche

A new website created by Roche Products (New Zealand) Ltd providing information on a previously misunderstood, but particularly aggressive form of breast cancer went live today. This website provides New Zealand women with a new resource in the fight ... More >>

PHARMAC shuts door on 400 New Zealand women

Monday, 16 October 2006, 4:09 pm | Roche

The government’s drug funding agency PHARMAC has confirmed it will not be funding Herceptin® (trastuzumab) for women with HER2 positive early breast cancer, making New Zealand the first country in the developed world to say ‘no’ to funding the ... More >>

Australian Govt Approves Herceptin Funding

Wednesday, 23 August 2006, 5:09 pm | Roche

Roche New Zealand notes that both the Australian Government and the UK National Institute of Health and Clinical Excellence (NICE) have approved funding for Herceptin for 12 months for women with early stage HER 2 positive breast cancer Roche New Zealand ... More >>

Roche committed to securing Herceptin funding

Friday, 28 July 2006, 3:44 pm | Roche

Roche Products (New Zealand) Ltd is disappointed by PHARMAC’s decision to decline funding of Herceptin (trastuzumab) for HER2-positive early breast cancer, but the company is committed to keeping its chair at the negotiating table until a positive ... More >>

Herceptin Approved for Early Breast Cancer In NZ

Friday, 24 March 2006, 8:37 am | Roche

Herceptin (trastuzumab) Approved for Early Breast Cancer in New Zealand Roche to focus on completing funding processes. More >>

Herceptin Approved for Early Breast Cancer in NZ

Thursday, 23 March 2006, 4:46 pm | Roche

Roche Products (New Zealand) Limited is pleased to confirm it has received regulatory approval for the use of Herceptin in HER2 positive early breast cancer. New Zealand is the first country in the world to achieve formal regulatory approval. More >>

Roche Position Statement Regarding Herceptin

Tuesday, 14 February 2006, 3:27 pm | Roche

Roche Products (NZ) Limited is working proactively and constructively with both Medsafe and Pharmac to ensure the fastest possible access to Herceptin for HER2 positive women with early breast cancer in New Zealand. The regulatory submission to permit ... More >>

Tamiflu supplies prioritised for flu season, govt

Friday, 25 November 2005, 12:21 am | Roche

Auckland, 25 November 2005 – Heightened interest in avian influenza has resulted in an unprecedented increase in demand for Tamiflu worldwide. Roche is therefore taking the step of prioritising its global production capacity of Tamiflu to ensure ... More >>

Open ended immunosuppressant access

Thursday, 29 September 2005, 12:35 am | Roche

New Zealand kidney and heart transplant patients will have open ended access to the immunosuppressant Cellcept®(mycophenolate mofetil) from October 1st. More >>

Collaboration on additional funding for treatment

Tuesday, 6 September 2005, 4:32 pm | Roche

Auckland, 6th September 2005 – Roche Products (New Zealand) Ltd and Government drug funding agency PHARMAC are working collaboratively, to ensure rapid assessment for funding of breast cancer treatment Herceptin (trastuzumab) for women ... More >>

$100,000 for HER2 breast cancer testing

Tuesday, 6 September 2005, 4:30 pm | Roche

$100,000 for HER2 breast cancer testing - Every woman with breast cancer can determine her HER2 status More >>

Research shows breast cancer reoccurrence halved

Friday, 3 June 2005, 10:53 am | Roche

Local research shows breast cancer reoccurrence rates halved New Zealand women and local researchers contribute to landmark study More >>

Xenical available from pharmacists

Friday, 11 March 2005, 1:52 pm | Roche

Auckland, March 10 2005 – Weight loss medication Xenical® (orlistat) is now available direct from a pharmacist for the first time in New Zealand. Xenical has been re-classified to a pharmacist only medicine meaning pharmacists can sell Xenical to appropriate ... More >>



InfoPages Links